SHAREHOLDER ALERT: Investigation of Osmotica Announced by Holzer & Holzer, LLC
ATLANTA--(BUSINESS WIRE)--Mar 28, 2019--Holzer & Holzer, LLC is investigating whether certain statements made by Osmotica Pharmaceuticals plc (“Osmotica” or the “Company”) (NASDAQ: OSMT) complied with federal securities laws. On March 27, 2019, after the markets closed, Osmotica announced preliminary results for a second Phase 3 clinical trial of arbaclofen extended-release tablets that failed to beat placebo as measured by the Clinical Global Impression of Change. The price of Osmotica stock declined following this news.
If you purchased Osmotica shares and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Marshall P. Dees, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190328005670/en/
CONTACT: Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
KEYWORD: UNITED STATES NORTH AMERICA GEORGIA
INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL
SOURCE: Holzer & Holzer, LLC
Copyright Business Wire 2019.
PUB: 03/28/2019 11:54 AM/DISC: 03/28/2019 11:54 AM